GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions

다국어 초록 (Multilingual Abstract)

With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management. Among incretin-based drugs, glucagon-like peptide 1 (GLP-1) receptor agonists are a promising therapeutic option for patients with diabetic kidney disease (DKD). Several cardiovascular outcome trials have demonstrated that GLP-1 receptor agonists have beneficial effects on cardiorenal outcomes beyond their blood glucose-lowering effects in patients with type 2 diabetes mellitus (T2DM). The renal protective effects of GLP-1 receptor agonists likely result from their direct actions on the kidney, in addition to their indirect actions that improve conventional risk factors for DKD, such as reducing blood glucose levels, blood pressure, and body weight. Inhibition of oxidative stress and inflammation and induction of natriuresis are major renoprotective mechanisms of GLP-1 analogues. Early evidence from the development of dual and triple combination agents suggests that GLP-1 receptor agonists will probably become popular treatment options for patients with T2DM.

참고문헌 (Reference)

1 Capozzi ME, "β Cell tone is defined by proglucagon peptides through cAMP signaling" 4 : e126742-, 2019

2 Liyanage T, "Worldwide access to treatment for end-stage kidney disease : a systematic review" 385 : 1975-1982, 2015

3 홍유아 ; 반태현 ; 강채영 ; Hwang Sun Deuk ; 최선령 ; 이하정 ; Jung Hee-Yeon ; 김경민 ; 권영은 ; 김수현 ; Kim Tae Hee ; Koo Ho-Seok ; Yoon Chang-Yun ; Kim Kiwon ; Park Jongha ; Kim Yong Kyun, "Trends in epidemiologic characteristics of end-stage renal disease from 2019 Korean Renal Data System (KORDS)" 대한신장학회 40 (40): 52-61, 2021

4 Tomotaka Yamazaki ; Imari Mimura ; Tetsuhiro Tanaka ; Masaomi Nangaku, "Treatment of Diabetic Kidney Disease: Current and Future" 대한당뇨병학회 45 (45): 11-26, 2021

5 Wei Y, "Tissue-specific expression of the human receptor for glucagon-like peptide-I : brain, heart and pancreatic forms have the same deduced amino acid sequences" 358 : 219-224, 1995

6 Drucker DJ, "The incretin system : glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes" 368 : 1696-1705, 2006

7 Finan B, "Targeted estrogen delivery reverses the metabolic syndrome" 18 : 1847-1856, 2012

8 Jouihan H, "Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice" 6 : 1360-1370, 2017

9 오태정 ; 문주영 ; Kyu Yeon Hur ; Seung Hyun Ko ; Hyun Jung Kim ; Taehee Kim ; Dong Won Lee ; Min Kyong Moon ; The Committee of Clinical Practice Guideline ; Korean Diabetes Association and Committee of the Cooperative Studies ; Korean Society of Nephrology, "Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement" 대한신장학회 39 (39): 269-286, 2020

10 Skov J, "Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes : a randomized clinical trial" 18 : 581-589, 2016

11 Marso SP, "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes" 375 : 1834-1844, 2016

12 Meier JJ, "Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects" 53 : 654-662, 2004

13 Orskov C, "Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day" 31 : 665-670, 1996

14 Neuen BL, "SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes : a systematic review and meta-analysis" 7 : 845-854, 2019

15 Coca SG, "Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus : systematic review and meta-analysis intensive glucose control in type 2 diabetes" 172 : 761-769, 2012

16 Müller TD, "Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21" 18 : 383-393, 2012

17 진동찬 ; 한진석, "Renal replacement therapy in Korea, 2012" 대한신장학회 33 (33): 9-18, 2014

18 Vitale M, "Renal protection with glucagon-like peptide-1 receptor agonists" 54 : 91-101, 2020

19 Roberge JN, "Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop" 133 : 233-240, 1993

20 Plaisancie P, "Regulation of glucagon-like peptide-1-(7-36)amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon" 135 : 2398-2403, 1994

21 Fujita H, "Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy" 34 : 1302-1308, 2011

22 Yip KP, "Redistribution of Na+/H+ exchanger isoform NHE3 in proximal tubules induced by acute and chronic hypertension" 275 : F565-F575, 1998

23 Yin W, "Protein kinase C and protein kinase A are involved in the protection of recombinant human glucagon-like peptide-1 on glomeruli and tubules in diabetic rats" 10 : 613-625, 2019

24 Ye Y, "Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-α-mediated NF-κB and MAPK pathway" 13 : 385-390, 2019

25 백인경, "Projection of Diabetes Prevalence in Korean Adults for the Year 2030 Using Risk Factors Identified from National Data" 대한당뇨병학회 43 (43): 90-96, 2019

26 Hare KJ, "Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus" 94 : 4679-4687, 2009

27 Elrick H, "Plasma insulin response to oral and intravenous glucose administration" 24 : 1076-1082, 1964

28 Neary NM, "Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively" 146 : 5120-5127, 2005

29 Husain M, "Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes" 381 : 841-851, 2019

30 Blonde L, "Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes(AWARD-4) : a randomised, open-label, phase 3, non-inferiority study" 385 : 2057-2066, 2015

31 Nauck M, "Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes : a 26-week randomized controlled clinical trial" 39 : 1501-1509, 2016

32 Mosterd CM, "Nephroprotective effects of GLP-1 receptor agonists : where do we stand?" 33 : 965-975, 2020

33 Quarta C, "Molecular integration of incretin and glucocorticoid action reverses immunometabolic dysfunction and obesity" 26 : 620-632, 2017

34 Bethel MA, "Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide : insights from the EXSCEL Trial" 43 : 446-452, 2020

35 Doyle ME, "Mechanisms of action of glucagon-like peptide 1 in the pancreas" 113 : 546-593, 2007

36 Crajoinas RO, "Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1" 301 : F355-F363, 2011

37 Kuhre RE, "Measurement of the incretin hormones : glucagon-like peptide-1 and glucose-dependent insulinotropic peptide" 29 : 445-450, 2015

38 Pfeffer MA, "Lixisenatide in patients with type 2 diabetes and acute coronary syndrome" 373 : 2247-2257, 2015

39 Muskiet MH, "Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome : an exploratory analysis of the ELIXA randomised, placebo-controlled trial" 6 : 859-869, 2018

40 Rizzo M, "Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes : a prospective pilot study" 100 : 603-606, 2015

41 Mann JF, "Liraglutide and renal outcomes in type 2 diabetes" 377 : 839-848, 2017

42 Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes" 375 : 311-322, 2016

43 Afkarian M, "Kidney disease and increased mortality risk in type 2 diabetes" 24 : 302-308, 2013

44 Kidney Disease : Improving Global Outcomes(KDIGO)Diabetes Work Group, "KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease" 98 (98): S1-S115, 2020

45 Gutzwiller JP, "Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men" 287 : R562-R567, 2004

46 Wøjdemann M, "Inhibition of human gastric lipase secretion by glucagon-like peptide-1" 43 : 799-805, 1998

47 Neumiller JJ, "Incretin pharmacology : a review of the incretin effect and current incretin-based therapies" 10 : 276-288, 2012

48 Trevaskis JL, "Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids" 8 : e78154-, 2013

49 Rask E, "Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men" 24 : 1640-1645, 2001

50 Kamanna VS, "Hyperlipidemia and kidney disease : concepts derived from histopathology and cell biology of the glomerulus" 13 : 169-179, 1998

51 Skov J, "Glucagon-like peptide-1(GLP-1) : effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men" 98 : E664-E671, 2013

52 Elliott RM, "Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man : acute post-prandial and 24-h secretion patterns" 138 : 159-166, 1993

53 Ben-Shlomo S, "Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase" 54 : 1214-1223, 2011

54 Li Y, "Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis" 278 : 471-478, 2003

55 Kodera R, "Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes" 54 : 965-978, 2011

56 Eissele R, "Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man" 22 : 283-291, 1992

57 Wang Y, "Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells" 136 : 4910-4917, 1995

58 Ronn J, "Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors" 5 : e13503-, 2017

59 Pocai A, "Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice" 58 : 2258-2266, 2009

60 Lim GE, "Glucagon-like peptide 1 secretion by the L-cell : the view from within" 55 (55): S70-S77, 2006

61 Schlatter P, "Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells" 141 : 120-128, 2007

62 von Scholten BJ, "Glucagon-like peptide 1 receptor agonist(GLP-1 RA) : long-term effect on kidney function in patients with type 2 diabetes" 29 : 670-674, 2015

63 Hogan AE, "Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus" 57 : 781-784, 2014

64 Buteau J, "GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival" 34 (34): S73-S77, 2008

65 Pyke C, "GLP-1 receptor localization in monkey and human tissue : novel distribution revealed with extensively validated monoclonal antibody" 155 : 1280-1290, 2014

66 Trujillo JM, "GLP-1 receptor agonists for type 2 diabetes mellitus : recent developments and emerging agents" 34 : 1174-1186, 2014

67 Meier JJ, "GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus" 8 : 728-742, 2012

68 Hendarto H, "GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases" 61 : 1422-1434, 2012

69 Jespersen MJ, "GLP-1 agonists for type 2 diabetes : pharmacokinetic and toxicological considerations" 9 : 17-29, 2013

70 Beiroa D, "GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK" 63 : 3346-3358, 2014

71 Asmar A, "Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1 : a functional GLP-1-renal axis in man" 104 : 2509-2519, 2019

72 Ding X, "Exendin-4, a glucagon-like protein-1(GLP-1)receptor agonist, reverses hepatic steatosis in ob/ob mice" 43 : 173-181, 2006

73 Xiao C, "Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans" 32 : 1513-1519, 2012

74 Muskiet MH, "Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus : a post-hoc analysis of a 52-week randomized trial" 153 : 14-22, 2019

75 Zhang H, "Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria" 35 : 483-488, 2012

76 Frías JP, "Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy(DURATION-8) : a 28 week, multicentre, double-blind, phase 3, randomised controlled trial" 4 : 1004-1016, 2016

77 Chaudhuri A, "Exenatide exerts a potent antiinflammatory effect" 97 : 198-207, 2012

78 Bunck MC, "Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition" 33 : 1734-1737, 2010

79 Chodorge M, "Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment" 8 : 17545-, 2018

80 Mosenzon O, "Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment(PIONEER 5) : a placebo-controlled, randomised, phase 3a trial" 7 : 515-527, 2019

81 Lingvay I, "Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes(SUSTAIN 8) : a double-blind, phase 3b, randomised controlled trial" 7 : 834-844, 2019

82 Frias JP, "Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes : a randomised, placebo-controlled and active comparator-controlled phase 2 trial" 392 : 2180-2193, 2018

83 Mann JF, "Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes : a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials" 8 : 880-893, 2020

84 Holman RR, "Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes" 377 : 1228-1239, 2017

85 Little TJ, "Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects : relationships with postprandial glycemic and insulinemic responses" 91 : 1916-1923, 2006

86 Dalsgaard NB, "Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors : a narrative review of head-to-head comparisons" 20 : 508-519, 2018

87 Tuttle KR, "Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus" 324 : 1626-1632, 1991

88 Sun F, "Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes : a systematic review and network meta-analysis" 37 : 225-241, 2015

89 Tuttle KR, "Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease(AWARD-7) : a multicentre, open-label, randomised trial" 6 : 605-617, 2018

90 Gerstein HC, "Dulaglutide and renal outcomes in type 2 diabetes : an exploratory analysis of the REWIND randomised, placebo-controlled trial" 394 : 131-138, 2019

91 Gerstein HC, "Dulaglutide and cardiovascular outcomes in type 2 diabetes(REWIND) : a double-blind, randomized placebo-controlled trial" 394 : 121-130, 2019

92 Clemmensen C, "Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice" 7 : 288-298, 2015

93 Alicic RZ, "Diabetic kidney disease : challenges, progress, and possibilities" 12 : 2032-2045, 2017

94 Sen Li ; Jiaxin Wang ; Biao Zhang ; Xinyi Li ; Yuan Liu, "Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study" 대한당뇨병학회 43 (43): 319-341, 2019

95 정찬희 ; 손장원 ; 강신애 ; 김원준 ; 김헌성 ; 김혜순 ; 서미혜 ; 신혜정 ; 이성수 ; 정수진 ; 조용인 ; 한승진 ; 장향미 ; 노미라 ; 이신비 ; 구미현 ; 유빈 ; 문정화 ; 이혜영 ; 윤재승 ; 김선영 ; 김성래 ; 정인경 ; 목지오 ; 윤건호, "Diabetes Fact Sheets in Korea, 2020: An Appraisal of Current Status" 대한당뇨병학회 45 (45): 1-10, 2021

96 Kieffer TJ, "Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV" 136 : 3585-3596, 1995

97 Deacon CF, "Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo" 80 : 952-957, 1995

98 Toft-Nielsen MB, "Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients" 22 : 1137-1143, 1999

99 Suarez-Pinzon WL, "Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice" 57 : 3281-3288, 2008

100 Balena R, "Combination therapy with GLP-1 receptor agonists and basal insulin : a systematic review of the literature" 15 : 485-502, 2013

101 Kooijman S, "Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice" 58 : 2637-2646, 2015

102 Kristensen SL, "Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials" 7 : 776-785, 2019

103 Gerstein HC, "Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes" 385 : 896-907, 2021

104 Hernandez AF, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease(Harmony Outcomes) : a double-blind, randomised placebo-controlled trial" 392 : 1519-1529, 2018

105 Bech EM, "Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice" 109 : 167-173, 2019

106 Madsen KB, "Acute effects of continuous infusions of glucagon-like peptide(GLP)-1, GLP-2 and the combination(GLP-1+GLP-2)on intestinal absorption in short bowel syndrome(SBS)patients : a placebo-controlled study" 184 : 30-39, 2013

107 Wang C, "Activation of the Nrf2-ARE pathway attenuates hyperglycemia-mediated injuries in mouse podocytes" 34 : 891-902, 2014

108 Zhou T, "Activation of Nrf2 contributes to the protective effect of Exendin-4 against angiotensin II-induced vascular smooth muscle cell senescence" 311 : C572-C582, 2016

109 Pan Q, "A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis" 63 : 103202-, 2021

110 American Diabetes Association, "9. Pharmacologic approaches to glycemic treatment : standards of medical care in diabetes-2021" 44 (44): S111-S124, 2021